Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Equity Average: 2017-2024

Historic Equity Average for Akebia Therapeutics (AKBA) over the last 8 years, with Dec 2024 value amounting to -$39.9 million.

  • Akebia Therapeutics' Equity Average rose 184.15% to $35.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.4 million, marking a year-over-year increase of 184.15%. This contributed to the annual value of -$39.9 million for FY2024, which is 214.62% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Equity Average of -$39.9 million as of FY2024, which was down 214.62% from -$12.7 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Equity Average registered a high of $319.6 million during FY2020, and its lowest value of -$39.9 million during FY2024.
  • For the 3-year period, Akebia Therapeutics' Equity Average averaged around -$4.3 million, with its median value being -$12.7 million (2023).
  • Data for Akebia Therapeutics' Equity Average shows a maximum YoY plummeted of 214.62% (in 2024) over the last 5 years.
  • Akebia Therapeutics' Equity Average (Yearly) stood at $319.6 million in 2020, then crashed by 50.19% to $159.2 million in 2021, then slumped by 75.11% to $39.6 million in 2022, then crashed by 132.00% to -$12.7 million in 2023, then slumped by 214.62% to -$39.9 million in 2024.